VNDA stock forecast, quote, news & analysis

Key Takeaways

• VNDA shares fell roughly 17% over the past 30 days, slipping from about $5.13 to near $4.25.
• A Phase III miss for anxiety candidate VQW-765 pressured sentiment after the company paused the program.
• A positive Phase III readout for HETLIOZ in delayed sleep-wake phase disorder provided support but did not halt the decline.
• The stock is trading near its 52-week low as investors weigh persistent cash burn ahead of the upcoming Q3 report.

Vanda Pharmaceuticals (VNDA) Company Overview and Market Position

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is a commercial-stage biopharmaceutical company headquartered in Washington, D.C., focused primarily on therapies for central nervous system disorders and other areas of high unmet medical need. Its marketed portfolio includes HETLIOZ (tasimelteon), indicated for non-24-hour sleep-wake disorder and Smith-Magenis Syndrome; Fanapt (iloperidone), an atypical antipsychotic for schizophrenia and bipolar I disorder; and PONVORY (ponesimod) for relapsing forms of multiple sclerosis. The company generates revenue mainly from product sales in the U.S. and select international markets, while advancing a clinical pipeline that has included candidates such as tradipitant and imsidolimab. Investors follow VNDA closely because of its small market capitalization, roughly $255 million, and the significant leverage that clinical and regulatory outcomes can have on its share price.

Vanda Pharmaceuticals (VNDA) Stock Price Performance: Last 30 Days vs. Quarter

Over the past 30 days, VNDA declined approximately 17%, moving from a closing price of $5.13 on September 18, 2026, to around $4.25 in late-October trading. The decline was not linear: shares held near the $5.00–$5.20 range through late September before a steady slide in October brought the stock toward its 52-week low near $4.22.

The broader quarterly trend has been similarly weak. From a closing level near $5.35 in late July, the stock has fallen roughly 21%, and it sits well below its early-July peak near $6.58. The multi-month downtrend reflects a combination of a disappointing second-quarter earnings report, clinical setbacks, and broader caution around small-cap biotech names.

What Drove VNDA Stock Price in the Last 30 Days

The most significant single event was the October 14, 2026, announcement that the Phase III trial of VQW-765, an investigational partial agonist targeting the alpha-7 nicotinic acetylcholine receptor, failed to meet its primary and key secondary endpoints in adults with social anxiety disorder. Vanda said it was pausing the program pending further data analysis, removing a speculative upside catalyst from the pipeline.

That setback was partially offset by positive news in late September, when Vanda reported that a Phase III study of HETLIOZ 20 mg met its primary endpoint in adults with delayed sleep-wake phase disorder (DSWPD), advancing sleep onset by roughly 37 minutes more than placebo. The company indicated plans to discuss the data with the U.S. Food and Drug Administration and pursue a supplemental New Drug Application.

Analyst actions were mixed. H.C. Wainwright reiterated a Buy rating with a $20 price target in early October, while Oppenheimer initiated coverage with an Outperform rating and a $10 target in late September. Despite these supportive calls, the broader decline suggests the market has remained focused on the company's ongoing losses and negative cash flow rather than near-term pipeline optionality.

What Drove VNDA Stock Performance Over the Last Quarter

The quarterly decline has deeper roots than the recent VQW-765 news. On August 5, 2026, Vanda reported second-quarter results that missed expectations, posting an adjusted loss of $1.04 per share versus a consensus estimate near $0.51 and revenue of roughly $50.5 million, below forecasts of about $61.8 million. HETLIOZ sales weighed on the quarter even as other products showed growth.

That earnings miss triggered a sharp selloff in early August, and shares failed to sustain any meaningful recovery through the remainder of the quarter. Persistent unprofitability, cash burn of more than $150 million on a trailing twelve-month basis, and uncertainty around the pipeline have kept sentiment subdued. The late-September DSWPD data offered a brief catalyst, but the October anxiety-trial failure reignited concerns about the company's development prospects.

Trending AI Robots

For traders seeking a data-driven approach to navigating volatile equities like Vanda, Tickeron's Trending AI Robots page offers a curated view of algorithmic trading strategies. Tickeron hosts hundreds of AI trading bots covering thousands of tickers, but only the top-performing and most relevant bots appear in this section. The featured robots vary in strategy, timeframe, and performance metrics, allowing users to compare approaches that range from short-term momentum to longer-horizon signals. Because the list is updated to reflect current performance, it can serve as a useful starting point for identifying strategies aligned with a particular market environment. Explore the page to see which AI-driven models are currently gaining traction across the market.

VNDA Stock Forecast Drivers: What Investors Should Watch Next

The next major checkpoint is Vanda's third-quarter earnings report, scheduled for November 4, 2026. Consensus estimates point to a loss of roughly $0.72 per share on revenue near $69 million, and investors will focus on HETLIOZ sales trends, spending discipline, and any updates to full-year guidance. The path forward for the HETLIOZ DSWPD supplemental application and the company's discussions with the FDA represent the most significant near-term regulatory catalysts.

Beyond earnings, investors should monitor cash runway and the pace of operating losses, as well as any additional pipeline readouts or partnership developments. With analyst price targets spanning a wide range from $5.75 to $20, the stock's valuation reflects meaningful uncertainty about the company's ability to return to profitability and broaden its commercial footprint. These are factors to watch, not investment recommendations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations